Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 51.32 USD 1.16%
Market Cap: 9.5B USD
Have any thoughts about
Exact Sciences Corp?
Write Note

Intrinsic Value

The intrinsic value of one EXAS stock under the Base Case scenario is 41.93 USD. Compared to the current market price of 51.32 USD, Exact Sciences Corp is Overvalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EXAS Intrinsic Value
41.93 USD
Overvaluation 18%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Exact Sciences Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for EXAS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about EXAS?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Exact Sciences Corp

Provide an overview of the primary business activities
of Exact Sciences Corp.

What unique competitive advantages
does Exact Sciences Corp hold over its rivals?

What risks and challenges
does Exact Sciences Corp face in the near future?

Summarize the latest earnings call
of Exact Sciences Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Exact Sciences Corp.

Provide P/S
for Exact Sciences Corp.

Provide P/E
for Exact Sciences Corp.

Provide P/OCF
for Exact Sciences Corp.

Provide P/FCFE
for Exact Sciences Corp.

Provide P/B
for Exact Sciences Corp.

Provide EV/S
for Exact Sciences Corp.

Provide EV/GP
for Exact Sciences Corp.

Provide EV/EBITDA
for Exact Sciences Corp.

Provide EV/EBIT
for Exact Sciences Corp.

Provide EV/OCF
for Exact Sciences Corp.

Provide EV/FCFF
for Exact Sciences Corp.

Provide EV/IC
for Exact Sciences Corp.

Show me price targets
for Exact Sciences Corp made by professional analysts.

What are the Revenue projections
for Exact Sciences Corp?

How accurate were the past Revenue estimates
for Exact Sciences Corp?

What are the Net Income projections
for Exact Sciences Corp?

How accurate were the past Net Income estimates
for Exact Sciences Corp?

What are the EPS projections
for Exact Sciences Corp?

How accurate were the past EPS estimates
for Exact Sciences Corp?

What are the EBIT projections
for Exact Sciences Corp?

How accurate were the past EBIT estimates
for Exact Sciences Corp?

Compare the revenue forecasts
for Exact Sciences Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Exact Sciences Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Exact Sciences Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Exact Sciences Corp compared to its peers.

Compare the P/E ratios
of Exact Sciences Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Exact Sciences Corp with its peers.

Analyze the financial leverage
of Exact Sciences Corp compared to its main competitors.

Show all profitability ratios
for Exact Sciences Corp.

Provide ROE
for Exact Sciences Corp.

Provide ROA
for Exact Sciences Corp.

Provide ROIC
for Exact Sciences Corp.

Provide ROCE
for Exact Sciences Corp.

Provide Gross Margin
for Exact Sciences Corp.

Provide Operating Margin
for Exact Sciences Corp.

Provide Net Margin
for Exact Sciences Corp.

Provide FCF Margin
for Exact Sciences Corp.

Show all solvency ratios
for Exact Sciences Corp.

Provide D/E Ratio
for Exact Sciences Corp.

Provide D/A Ratio
for Exact Sciences Corp.

Provide Interest Coverage Ratio
for Exact Sciences Corp.

Provide Altman Z-Score Ratio
for Exact Sciences Corp.

Provide Quick Ratio
for Exact Sciences Corp.

Provide Current Ratio
for Exact Sciences Corp.

Provide Cash Ratio
for Exact Sciences Corp.

What is the historical Revenue growth
over the last 5 years for Exact Sciences Corp?

What is the historical Net Income growth
over the last 5 years for Exact Sciences Corp?

What is the current Free Cash Flow
of Exact Sciences Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Exact Sciences Corp.

Business Breakdown

Exact Sciences Corp. is a pioneering diagnostics company that focuses on the early detection and prevention of colorectal cancer, which is one of the deadliest cancers in the world. Founded in 1995 and based in Madison, Wisconsin, Exact Sciences made significant strides with its flagship product, Cologuard, the first non-invasive stool-based DNA test approved by the FDA for colorectal cancer screening. By combining advanced molecular biology and genetic testing, the company aims to enhance the efficiency and effectiveness of cancer screening processes, ultimately saving lives and reducing healthcare costs. This innovation has positioned Exact Sciences as a leader in preventive healthcare, ca...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Exact Sciences Corp

Current Assets 1.5B
Cash & Short-Term Investments 1B
Receivables 264.8m
Other Current Assets 247.2m
Non-Current Assets 5.2B
PP&E 834.4m
Intangibles 4.2B
Other Non-Current Assets 149.2m
Current Liabilities 723.7m
Accounts Payable 97.7m
Accrued Liabilities 341.2m
Other Current Liabilities 284.8m
Non-Current Liabilities 2.8B
Long-Term Debt 2.3B
Other Non-Current Liabilities 480.1m
Efficiency

Earnings Waterfall
Exact Sciences Corp

Revenue
2.7B USD
Cost of Revenue
-727.9m USD
Gross Profit
2B USD
Operating Expenses
-2.2B USD
Operating Income
-208.9m USD
Other Expenses
-5.1m USD
Net Income
-214m USD

Free Cash Flow Analysis
Exact Sciences Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

EXAS Profitability Score
Profitability Due Diligence

Exact Sciences Corp's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
36/100
Profitability
Score

Exact Sciences Corp's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

EXAS Solvency Score
Solvency Due Diligence

Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Positive Net Debt
41/100
Solvency
Score

Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EXAS Price Targets Summary
Exact Sciences Corp

Wall Street analysts forecast EXAS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXAS is 81.05 USD with a low forecast of 61.61 USD and a high forecast of 105 USD.

Lowest
Price Target
61.61 USD
20% Upside
Average
Price Target
81.05 USD
58% Upside
Highest
Price Target
105 USD
105% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for EXAS?

Click here to dive deeper.

Dividends

Exact Sciences Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for EXAS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

EXAS News

Other Videos

Profile

Exact Sciences Corp Logo
Exact Sciences Corp

Country

United States of America

Industry

Biotechnology

Market Cap

9.5B USD

Dividend Yield

0%

Description

EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. The company is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.

Contact

WISCONSIN
Madison
5505 Endeavor Lane
+16082845700.0
www.exactsciences.com

IPO

2001-01-30

Employees

6 420

Officers

Chairman of The Board & CEO
Mr. Kevin T. Conroy
Executive VP & GM of Screening
Mr. Jake Orville MBA
Executive VP & General Manager of Precision Oncology
Mr. Brian Baranick
Executive Vice President of Finance
Mr. Aaron Bloomer
Chief Science Officer
Dr. Jorge A. Garces Ph.D.
Chief Information Officer
Mr. Nassar Nizami
Show More
Associate Manager of Investor Relations
Ms. Megan Jones
Chief Compliance Counsel & VP
Mr. Tim Caprez
Senior VP, General Counsel & Secretary
Mr. James Herriott
Executive Vice President of Human Resources
Ms. Sarah Condella
Show Less

See Also

Discover More
What is the Intrinsic Value of one EXAS stock?

The intrinsic value of one EXAS stock under the Base Case scenario is 41.93 USD.

Is EXAS stock undervalued or overvalued?

Compared to the current market price of 51.32 USD, Exact Sciences Corp is Overvalued by 18%.

Back to Top